Skip to main content
Top
Published in: Current Atherosclerosis Reports 4/2010

01-07-2010

Hyperlipidemia and Primary Prevention of Stroke: Does Risk Factor Identification and Reduction Really Work?

Authors: Ariane Lewis, Alan Segal

Published in: Current Atherosclerosis Reports | Issue 4/2010

Login to get access

Abstract

Stroke is one of the leading causes of death. Hyperlipidemia is a major risk factor for stroke. The United States Preventive Service Task Force defines lipid screening guidelines. Treatment options of hyperlipidemia include lifestyle modifications and medical management. Statins have been shown to decrease lipids and exert a pleiotropic effect on intracranial vasculature and inflammatory modulators, leading to neuroprotection. Lower low-density lipoprotein and higher high-density lipoprotein levels are associated with decreased risk of stroke. Despite screening guidelines and evidence of the efficacy of statins, there are numerous barriers to maintaining adequate control of lipids.
Literature
1.
go back to reference •• Lloyd-Jones D, Adams R, Brown T, et al.: Heart Disease and Stroke Statistics 2010 Update. A Report From the American Heart Association. Circulation 2010, 121:e1–e170. This article includes a thorough summary of the most up-to-date statistics on heart disease and stroke. •• Lloyd-Jones D, Adams R, Brown T, et al.: Heart Disease and Stroke Statistics 2010 Update. A Report From the American Heart Association. Circulation 2010, 121:e1–e170. This article includes a thorough summary of the most up-to-date statistics on heart disease and stroke.
2.
go back to reference Castilla-Guerra L, Fernandez-Moreno M, Alvarez-Suero J: Secondary stroke prevention in the elderly: New evidence in hypertension and hyperlipidemia. Eur J Intern Med 2009, 20:586–590.CrossRefPubMed Castilla-Guerra L, Fernandez-Moreno M, Alvarez-Suero J: Secondary stroke prevention in the elderly: New evidence in hypertension and hyperlipidemia. Eur J Intern Med 2009, 20:586–590.CrossRefPubMed
5.
go back to reference Goldstein LB: Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep 2009, 11:296–300.CrossRefPubMed Goldstein LB: Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep 2009, 11:296–300.CrossRefPubMed
6.
go back to reference Rodriguez-Yanez M, Agulla J, Rodriguez-Gonzalez R, et al.: Statins and stroke. Ther Adv Cardiovasc Dis 2008, 2:157–166.CrossRefPubMed Rodriguez-Yanez M, Agulla J, Rodriguez-Gonzalez R, et al.: Statins and stroke. Ther Adv Cardiovasc Dis 2008, 2:157–166.CrossRefPubMed
7.
go back to reference Jones P, Kafonek S, Laurora I, et al.: Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients with Hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81:582–587.CrossRefPubMed Jones P, Kafonek S, Laurora I, et al.: Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients with Hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81:582–587.CrossRefPubMed
8.
go back to reference Crouse JR, Frohlich J, Ose L, et al.: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol 1999, 83:1476–1477.CrossRefPubMed Crouse JR, Frohlich J, Ose L, et al.: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol 1999, 83:1476–1477.CrossRefPubMed
9.
go back to reference Foody JM, Joyce A, Rudolph A, et al.: Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the united states. Clin Ther 2008; 30:195–205.CrossRefPubMed Foody JM, Joyce A, Rudolph A, et al.: Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the united states. Clin Ther 2008; 30:195–205.CrossRefPubMed
10.
go back to reference Horimoto Y, Matsubara M, Mizutani H, et al.: Effects of pitavastatin on cerebral blood flow. Clin Ther 2009, 31:575–579.CrossRefPubMed Horimoto Y, Matsubara M, Mizutani H, et al.: Effects of pitavastatin on cerebral blood flow. Clin Ther 2009, 31:575–579.CrossRefPubMed
11.
go back to reference Tan T, Kuo YL, Lin WC, et al.: Effect of lipid-lowering therapy on progression of intracranial arterial stenosis. J Neurol 2009, 256:187–193.CrossRefPubMed Tan T, Kuo YL, Lin WC, et al.: Effect of lipid-lowering therapy on progression of intracranial arterial stenosis. J Neurol 2009, 256:187–193.CrossRefPubMed
12.
go back to reference Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed].Lancet 1994, 344:1383–139. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed].Lancet 1994, 344:1383–139.
13.
go back to reference •• Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet 2009,8:453–463. This meta-analysis summarizes the results of 24 studies on the impact of lipid control on strokes. •• Amarenco P, Labreuche J: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet 2009,8:453–463. This meta-analysis summarizes the results of 24 studies on the impact of lipid control on strokes.
14.
go back to reference Gardener H, Della Morte D, Elkind M, et al.: Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc Disord 2009, 9:55.CrossRefPubMed Gardener H, Della Morte D, Elkind M, et al.: Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc Disord 2009, 9:55.CrossRefPubMed
15.
go back to reference Asplund K, Karvanen J, Giampaoli S, et al.: Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009, 40:2319–2326.CrossRefPubMed Asplund K, Karvanen J, Giampaoli S, et al.: Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009, 40:2319–2326.CrossRefPubMed
16.
go back to reference Pilote L, Dasgupta K, Guru V, et al.: A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007, 176:S1–S44.PubMed Pilote L, Dasgupta K, Guru V, et al.: A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007, 176:S1–S44.PubMed
17.
go back to reference Yu AY, Keezer MR, Zhu B, et al.: Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc Dis 2009, 27:398–402.CrossRefPubMed Yu AY, Keezer MR, Zhu B, et al.: Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc Dis 2009, 27:398–402.CrossRefPubMed
18.
go back to reference Fuentes B, Martinez-Sanchez P, Diez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009, 27(Suppl 1):126–133.CrossRefPubMed Fuentes B, Martinez-Sanchez P, Diez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009, 27(Suppl 1):126–133.CrossRefPubMed
19.
go back to reference Prinz V, Endres M: The acute (cerebro)vascular effects of statins. Anesth Analg 2009; 109:572–584.CrossRefPubMed Prinz V, Endres M: The acute (cerebro)vascular effects of statins. Anesth Analg 2009; 109:572–584.CrossRefPubMed
20.
go back to reference Goldstein L, Amarenco P, Zivin J, et al.: Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009, 40:3526–3531.CrossRefPubMed Goldstein L, Amarenco P, Zivin J, et al.: Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009, 40:3526–3531.CrossRefPubMed
21.
go back to reference LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005, 352:1425–1435.CrossRefPubMed LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005, 352:1425–1435.CrossRefPubMed
22.
go back to reference Ridker P: Moving toward new statin guidelines in a Post-JUPITER World: principles to consider. Curr Atherscler Rep 2009, 11:249–256.CrossRef Ridker P: Moving toward new statin guidelines in a Post-JUPITER World: principles to consider. Curr Atherscler Rep 2009, 11:249–256.CrossRef
23.
go back to reference John S, Schneider M, Delles C, et al.: Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005, 149:473.e1–e10.CrossRef John S, Schneider M, Delles C, et al.: Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005, 149:473.e1–e10.CrossRef
24.
go back to reference Nolte CH, Jungehulsing J, Rossnagel K, et al.: Vascular risk factor awareness before and pharmacological treatment before and after stroke and TIA. Eur J Neurol 2009, 16:678–683.CrossRefPubMed Nolte CH, Jungehulsing J, Rossnagel K, et al.: Vascular risk factor awareness before and pharmacological treatment before and after stroke and TIA. Eur J Neurol 2009, 16:678–683.CrossRefPubMed
25.
go back to reference Lewis SJ, Robinson JG, Fox KM, et al.: Underutilisation of cardiovascular medications among at-risk individuals. Int J Clin Pract 2009 (in press). Lewis SJ, Robinson JG, Fox KM, et al.: Underutilisation of cardiovascular medications among at-risk individuals. Int J Clin Pract 2009 (in press).
26.
go back to reference • Romero JR, Morris J, Pikula A: Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2008, 2:287–303. This review article addresses stroke risk factors and primary and secondary prevention. • Romero JR, Morris J, Pikula A: Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2008, 2:287–303. This review article addresses stroke risk factors and primary and secondary prevention.
27.
go back to reference Labarthe D, Dai S, Day R, et al.: Findings from Project HeartBeat! Their importance for CVD prevention. Am J Prev Med 2009, 37(Suppl 1):S105–115.CrossRefPubMed Labarthe D, Dai S, Day R, et al.: Findings from Project HeartBeat! Their importance for CVD prevention. Am J Prev Med 2009, 37(Suppl 1):S105–115.CrossRefPubMed
Metadata
Title
Hyperlipidemia and Primary Prevention of Stroke: Does Risk Factor Identification and Reduction Really Work?
Authors
Ariane Lewis
Alan Segal
Publication date
01-07-2010
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 4/2010
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-010-0117-4

Other articles of this Issue 4/2010

Current Atherosclerosis Reports 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine